Toniv,

A few comments. The anacetrapib/REVEAL trial is a MACE trial. It is already known that it raises HDL, and very successfully. The main question is whether it is functional HDL that assists in reducing MACE. One major concern of anacetrapib is that is has a VERY long half life that results in levels of the drug (and higher HDL) persisting for months and even years after cessation of taking the drug.

We already have some clues about Anacetrapib. The Phase III DEFINE trial (Anacetrapib) found that at 76 weeks post-treatment as well as after an additional 2-year extension that the placebo and anacetrapib groups both had similar cardiovascular events.

Best regards,

BearDownAZ